Global Monogenetic Disorders Testing
Global Monogenetic Disorders Testing

Monogenetic Disorders Testing Comprehensive Study by Type (Carrier Testing, Diagnostic Testing, New-Born Screening, Predictive & Pre-Symptomatic Testing, Prenatal Testing, Others), Application (Hospitals, Specialized Clinics, Ambulatory Surgical Centers), Disorder (Cystic fibrosis, Sickle Cell Anemia, Severe Combined Immunodeficiency (SCID), Tay-sachs Disorder, Polycystic Kidney Disorder, Gaucher's Disease, Huntington's Disease, Neurofibromatosis, Thalassaemia, Familial Hypercholesterolemia) Players and Region - Global Market Outlook to 2024

Monogenetic Disorders Testing Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Sep 2019 Edition 217 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Market Snapshot:
Monogenetic disorders testing is refer to as the procedure of testing a disorder related to monogenetic. While the monogenetic disorder is inherited because of the single defective gene on the autosomes. Monogenic disorders are caused by a single mutated gene which is present either on single or both chromosomes. Males and females are equally affected by such kind of disorder due to the conditions on autosomes. Some of the tests available for the mainstream of the common monogenic disorders are Cystic fibrosis, SCID, Tay-sachs disease, polycystic kidney disorder, sickle cell anemia, Gaucher's disease, Huntington's disease, thalassaemia, neurofibromatosis, and familial hypercholesterolemia.

Market Drivers
  • Rising awareness of genetic disorders among the population
  • Availability of advanced technological platforms and improved genomic tools

Market Trend
  • Increasing prevalence of monogenic disorders throughout the globe

Restraints
  • Lack of skilled professionals, and lack of knowledge

Opportunities
Increasing investment by the hospital facilities and government for better healthcare

Players Covered in the Study are:
Celera Group (United States), Abbott (United States), Thermo Fisher Scientific (United States), ELITech Group (France), DescriptionQuest Diagnostics (United States), AutoGenomics (United States), PerkinElmer (United States), Roche (Switzerland) and Bio-Rad (United States)


Report Objectives / Segmentation Covered
By Type
  • Carrier Testing
  • Diagnostic Testing
  • New-Born Screening
  • Predictive & Pre-Symptomatic Testing
  • Prenatal Testing
  • Others
By Application
  • Hospitals
  • Specialized Clinics
  • Ambulatory Surgical Centers
By Disorder
  • Cystic fibrosis
  • Sickle Cell Anemia
  • Severe Combined Immunodeficiency (SCID)
  • Tay-sachs Disorder
  • Polycystic Kidney Disorder
  • Gaucher's Disease
  • Huntington's Disease
  • Neurofibromatosis
  • Thalassaemia
  • Familial Hypercholesterolemia

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising awareness of genetic disorders among the population
      • 3.2.2. Availability of advanced technological platforms and improved genomic tools
    • 3.3. Market Challenges
      • 3.3.1. High cost associated with the testing procedure
    • 3.4. Market Trends
      • 3.4.1. Increasing prevalence of monogenic disorders throughout the globe
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Monogenetic Disorders Testing, by Type, Application, Disorder and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Monogenetic Disorders Testing (Value)
      • 5.2.1. Global Monogenetic Disorders Testing by: Type (Value)
        • 5.2.1.1. Carrier Testing
        • 5.2.1.2. Diagnostic Testing
        • 5.2.1.3. New-Born Screening
        • 5.2.1.4. Predictive & Pre-Symptomatic Testing
        • 5.2.1.5. Prenatal Testing
        • 5.2.1.6. Others
      • 5.2.2. Global Monogenetic Disorders Testing by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Specialized Clinics
        • 5.2.2.3. Ambulatory Surgical Centers
      • 5.2.3. Global Monogenetic Disorders Testing by: Disorder (Value)
        • 5.2.3.1. Cystic fibrosis
        • 5.2.3.2. Sickle Cell Anemia
        • 5.2.3.3. Severe Combined Immunodeficiency (SCID)
        • 5.2.3.4. Tay-sachs Disorder
        • 5.2.3.5. Polycystic Kidney Disorder
        • 5.2.3.6. Gaucher's Disease
        • 5.2.3.7. Huntington's Disease
        • 5.2.3.8. Neurofibromatosis
        • 5.2.3.9. Thalassaemia
        • 5.2.3.10. Familial Hypercholesterolemia
      • 5.2.4. Global Monogenetic Disorders Testing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Monogenetic Disorders Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Celera Group (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. ELITech Group (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. DescriptionQuest Diagnostics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AutoGenomics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. PerkinElmer (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Roche (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bio-Rad (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Monogenetic Disorders Testing Sale, by Type, Application, Disorder and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Monogenetic Disorders Testing (Value)
      • 7.2.1. Global Monogenetic Disorders Testing by: Type (Value)
        • 7.2.1.1. Carrier Testing
        • 7.2.1.2. Diagnostic Testing
        • 7.2.1.3. New-Born Screening
        • 7.2.1.4. Predictive & Pre-Symptomatic Testing
        • 7.2.1.5. Prenatal Testing
        • 7.2.1.6. Others
      • 7.2.2. Global Monogenetic Disorders Testing by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Specialized Clinics
        • 7.2.2.3. Ambulatory Surgical Centers
      • 7.2.3. Global Monogenetic Disorders Testing by: Disorder (Value)
        • 7.2.3.1. Cystic fibrosis
        • 7.2.3.2. Sickle Cell Anemia
        • 7.2.3.3. Severe Combined Immunodeficiency (SCID)
        • 7.2.3.4. Tay-sachs Disorder
        • 7.2.3.5. Polycystic Kidney Disorder
        • 7.2.3.6. Gaucher's Disease
        • 7.2.3.7. Huntington's Disease
        • 7.2.3.8. Neurofibromatosis
        • 7.2.3.9. Thalassaemia
        • 7.2.3.10. Familial Hypercholesterolemia
      • 7.2.4. Global Monogenetic Disorders Testing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Monogenetic Disorders Testing: by Type(USD Million)
  • Table 2. Monogenetic Disorders Testing Carrier Testing , by Region USD Million (2013-2018)
  • Table 3. Monogenetic Disorders Testing Diagnostic Testing , by Region USD Million (2013-2018)
  • Table 4. Monogenetic Disorders Testing New-Born Screening , by Region USD Million (2013-2018)
  • Table 5. Monogenetic Disorders Testing Predictive & Pre-Symptomatic Testing , by Region USD Million (2013-2018)
  • Table 6. Monogenetic Disorders Testing Prenatal Testing , by Region USD Million (2013-2018)
  • Table 7. Monogenetic Disorders Testing Others , by Region USD Million (2013-2018)
  • Table 8. Monogenetic Disorders Testing: by Application(USD Million)
  • Table 9. Monogenetic Disorders Testing Hospitals , by Region USD Million (2013-2018)
  • Table 10. Monogenetic Disorders Testing Specialized Clinics , by Region USD Million (2013-2018)
  • Table 11. Monogenetic Disorders Testing Ambulatory Surgical Centers , by Region USD Million (2013-2018)
  • Table 12. Monogenetic Disorders Testing: by Disorder(USD Million)
  • Table 13. Monogenetic Disorders Testing Cystic fibrosis , by Region USD Million (2013-2018)
  • Table 14. Monogenetic Disorders Testing Sickle Cell Anemia , by Region USD Million (2013-2018)
  • Table 15. Monogenetic Disorders Testing Severe Combined Immunodeficiency (SCID) , by Region USD Million (2013-2018)
  • Table 16. Monogenetic Disorders Testing Tay-sachs Disorder , by Region USD Million (2013-2018)
  • Table 17. Monogenetic Disorders Testing Polycystic Kidney Disorder , by Region USD Million (2013-2018)
  • Table 18. Monogenetic Disorders Testing Gaucher's Disease , by Region USD Million (2013-2018)
  • Table 19. Monogenetic Disorders Testing Huntington's Disease , by Region USD Million (2013-2018)
  • Table 20. Monogenetic Disorders Testing Neurofibromatosis , by Region USD Million (2013-2018)
  • Table 21. Monogenetic Disorders Testing Thalassaemia , by Region USD Million (2013-2018)
  • Table 22. Monogenetic Disorders Testing Familial Hypercholesterolemia , by Region USD Million (2013-2018)
  • Table 23. South America Monogenetic Disorders Testing, by Country USD Million (2013-2018)
  • Table 24. South America Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 25. South America Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 26. South America Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 27. Brazil Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 28. Brazil Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 29. Brazil Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 30. Argentina Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 31. Argentina Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 32. Argentina Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 33. Rest of South America Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 34. Rest of South America Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 35. Rest of South America Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 36. Asia Pacific Monogenetic Disorders Testing, by Country USD Million (2013-2018)
  • Table 37. Asia Pacific Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 38. Asia Pacific Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 39. Asia Pacific Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 40. China Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 41. China Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 42. China Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 43. Japan Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 44. Japan Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 45. Japan Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 46. India Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 47. India Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 48. India Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 49. South Korea Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 50. South Korea Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 51. South Korea Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 52. Taiwan Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 53. Taiwan Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 54. Taiwan Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 55. Australia Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 56. Australia Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 57. Australia Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 58. Rest of Asia-Pacific Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 59. Rest of Asia-Pacific Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 60. Rest of Asia-Pacific Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 61. Europe Monogenetic Disorders Testing, by Country USD Million (2013-2018)
  • Table 62. Europe Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 63. Europe Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 64. Europe Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 65. Germany Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 66. Germany Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 67. Germany Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 68. France Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 69. France Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 70. France Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 71. Italy Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 72. Italy Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 73. Italy Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 74. United Kingdom Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 75. United Kingdom Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 76. United Kingdom Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 77. Netherlands Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 78. Netherlands Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 79. Netherlands Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 80. Rest of Europe Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 81. Rest of Europe Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 82. Rest of Europe Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 83. MEA Monogenetic Disorders Testing, by Country USD Million (2013-2018)
  • Table 84. MEA Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 85. MEA Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 86. MEA Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 87. Middle East Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 88. Middle East Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 89. Middle East Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 90. Africa Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 91. Africa Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 92. Africa Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 93. North America Monogenetic Disorders Testing, by Country USD Million (2013-2018)
  • Table 94. North America Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 95. North America Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 96. North America Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 97. United States Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 98. United States Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 99. United States Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 100. Canada Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 101. Canada Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 102. Canada Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 103. Mexico Monogenetic Disorders Testing, by Type USD Million (2013-2018)
  • Table 104. Mexico Monogenetic Disorders Testing, by Application USD Million (2013-2018)
  • Table 105. Mexico Monogenetic Disorders Testing, by Disorder USD Million (2013-2018)
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Monogenetic Disorders Testing: by Type(USD Million)
  • Table 116. Monogenetic Disorders Testing Carrier Testing , by Region USD Million (2019-2024)
  • Table 117. Monogenetic Disorders Testing Diagnostic Testing , by Region USD Million (2019-2024)
  • Table 118. Monogenetic Disorders Testing New-Born Screening , by Region USD Million (2019-2024)
  • Table 119. Monogenetic Disorders Testing Predictive & Pre-Symptomatic Testing , by Region USD Million (2019-2024)
  • Table 120. Monogenetic Disorders Testing Prenatal Testing , by Region USD Million (2019-2024)
  • Table 121. Monogenetic Disorders Testing Others , by Region USD Million (2019-2024)
  • Table 122. Monogenetic Disorders Testing: by Application(USD Million)
  • Table 123. Monogenetic Disorders Testing Hospitals , by Region USD Million (2019-2024)
  • Table 124. Monogenetic Disorders Testing Specialized Clinics , by Region USD Million (2019-2024)
  • Table 125. Monogenetic Disorders Testing Ambulatory Surgical Centers , by Region USD Million (2019-2024)
  • Table 126. Monogenetic Disorders Testing: by Disorder(USD Million)
  • Table 127. Monogenetic Disorders Testing Cystic fibrosis , by Region USD Million (2019-2024)
  • Table 128. Monogenetic Disorders Testing Sickle Cell Anemia , by Region USD Million (2019-2024)
  • Table 129. Monogenetic Disorders Testing Severe Combined Immunodeficiency (SCID) , by Region USD Million (2019-2024)
  • Table 130. Monogenetic Disorders Testing Tay-sachs Disorder , by Region USD Million (2019-2024)
  • Table 131. Monogenetic Disorders Testing Polycystic Kidney Disorder , by Region USD Million (2019-2024)
  • Table 132. Monogenetic Disorders Testing Gaucher's Disease , by Region USD Million (2019-2024)
  • Table 133. Monogenetic Disorders Testing Huntington's Disease , by Region USD Million (2019-2024)
  • Table 134. Monogenetic Disorders Testing Neurofibromatosis , by Region USD Million (2019-2024)
  • Table 135. Monogenetic Disorders Testing Thalassaemia , by Region USD Million (2019-2024)
  • Table 136. Monogenetic Disorders Testing Familial Hypercholesterolemia , by Region USD Million (2019-2024)
  • Table 137. South America Monogenetic Disorders Testing, by Country USD Million (2019-2024)
  • Table 138. South America Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 139. South America Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 140. South America Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 141. Brazil Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 142. Brazil Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 143. Brazil Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 144. Argentina Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 145. Argentina Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 146. Argentina Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 147. Rest of South America Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 148. Rest of South America Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 149. Rest of South America Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 150. Asia Pacific Monogenetic Disorders Testing, by Country USD Million (2019-2024)
  • Table 151. Asia Pacific Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 152. Asia Pacific Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 153. Asia Pacific Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 154. China Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 155. China Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 156. China Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 157. Japan Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 158. Japan Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 159. Japan Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 160. India Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 161. India Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 162. India Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 163. South Korea Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 164. South Korea Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 165. South Korea Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 166. Taiwan Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 167. Taiwan Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 168. Taiwan Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 169. Australia Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 170. Australia Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 171. Australia Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 172. Rest of Asia-Pacific Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 173. Rest of Asia-Pacific Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 174. Rest of Asia-Pacific Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 175. Europe Monogenetic Disorders Testing, by Country USD Million (2019-2024)
  • Table 176. Europe Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 177. Europe Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 178. Europe Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 179. Germany Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 180. Germany Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 181. Germany Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 182. France Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 183. France Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 184. France Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 185. Italy Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 186. Italy Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 187. Italy Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 188. United Kingdom Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 189. United Kingdom Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 190. United Kingdom Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 191. Netherlands Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 192. Netherlands Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 193. Netherlands Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 194. Rest of Europe Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 195. Rest of Europe Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 196. Rest of Europe Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 197. MEA Monogenetic Disorders Testing, by Country USD Million (2019-2024)
  • Table 198. MEA Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 199. MEA Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 200. MEA Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 201. Middle East Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 202. Middle East Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 203. Middle East Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 204. Africa Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 205. Africa Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 206. Africa Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 207. North America Monogenetic Disorders Testing, by Country USD Million (2019-2024)
  • Table 208. North America Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 209. North America Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 210. North America Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 211. United States Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 212. United States Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 213. United States Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 214. Canada Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 215. Canada Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 216. Canada Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 217. Mexico Monogenetic Disorders Testing, by Type USD Million (2019-2024)
  • Table 218. Mexico Monogenetic Disorders Testing, by Application USD Million (2019-2024)
  • Table 219. Mexico Monogenetic Disorders Testing, by Disorder USD Million (2019-2024)
  • Table 220. Research Programs/Design for This Report
  • Table 221. Key Data Information from Secondary Sources
  • Table 222. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Monogenetic Disorders Testing: by Type USD Million (2013-2018)
  • Figure 5. Global Monogenetic Disorders Testing: by Application USD Million (2013-2018)
  • Figure 6. Global Monogenetic Disorders Testing: by Disorder USD Million (2013-2018)
  • Figure 7. South America Monogenetic Disorders Testing Share (%), by Country
  • Figure 8. Asia Pacific Monogenetic Disorders Testing Share (%), by Country
  • Figure 9. Europe Monogenetic Disorders Testing Share (%), by Country
  • Figure 10. MEA Monogenetic Disorders Testing Share (%), by Country
  • Figure 11. North America Monogenetic Disorders Testing Share (%), by Country
  • Figure 12. Global Monogenetic Disorders Testing share by Players 2018 (%)
  • Figure 13. Global Monogenetic Disorders Testing share by Players (Top 3) 2018(%)
  • Figure 14. Global Monogenetic Disorders Testing share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Celera Group (United States) Revenue, Net Income and Gross profit
  • Figure 17. Celera Group (United States) Revenue: by Geography 2018
  • Figure 18. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott (United States) Revenue: by Geography 2018
  • Figure 20. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 21. Thermo Fisher Scientific (United States) Revenue: by Geography 2018
  • Figure 22. ELITech Group (France) Revenue, Net Income and Gross profit
  • Figure 23. ELITech Group (France) Revenue: by Geography 2018
  • Figure 24. DescriptionQuest Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 25. DescriptionQuest Diagnostics (United States) Revenue: by Geography 2018
  • Figure 26. AutoGenomics (United States) Revenue, Net Income and Gross profit
  • Figure 27. AutoGenomics (United States) Revenue: by Geography 2018
  • Figure 28. PerkinElmer (United States) Revenue, Net Income and Gross profit
  • Figure 29. PerkinElmer (United States) Revenue: by Geography 2018
  • Figure 30. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Roche (Switzerland) Revenue: by Geography 2018
  • Figure 32. Bio-Rad (United States) Revenue, Net Income and Gross profit
  • Figure 33. Bio-Rad (United States) Revenue: by Geography 2018
  • Figure 34. Global Monogenetic Disorders Testing: by Type USD Million (2019-2024)
  • Figure 35. Global Monogenetic Disorders Testing: by Application USD Million (2019-2024)
  • Figure 36. Global Monogenetic Disorders Testing: by Disorder USD Million (2019-2024)
  • Figure 37. South America Monogenetic Disorders Testing Share (%), by Country
  • Figure 38. Asia Pacific Monogenetic Disorders Testing Share (%), by Country
  • Figure 39. Europe Monogenetic Disorders Testing Share (%), by Country
  • Figure 40. MEA Monogenetic Disorders Testing Share (%), by Country
  • Figure 41. North America Monogenetic Disorders Testing Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Celera Group (United States)
  • Abbott (United States)
  • Thermo Fisher Scientific (United States)
  • ELITech Group (France)
  • DescriptionQuest Diagnostics (United States)
  • AutoGenomics (United States)
  • PerkinElmer (United States)
  • Roche (Switzerland)
  • Bio-Rad (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation